PBAC's latest decision on Sunitinib: Recommended (2013). Considered for Initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET) in patients who are symptomatic despite somatostatin analogues or who have documented disease progression.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
$75k/QALY
$45k/QALY–$75k/QALY · across 2 submissions
Submissions
2
first 2012
Submissions
2
2012 → 2013
Eligible population
Adults with metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET) who are symptomatic despite somatostatin analogues or have documented disease progression.
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
OS
Comparator
best supportive care/placebo
Economic model
CUA
ICER basis
Range aggregates 2 submissions (2012–2013) — not a single base case.
Risk sharing
Risk-sharing arrangement in place — The sponsor offered to renegotiate the current risk share arrangement to include sunitinib for pNET.
Submission history
Jul 2012: Not recommended — ICER $75k/QALY
Aug 2013: Recommended · Authority Required — ICER $75k/QALY